CoreWeave vs Inovio Pharmaceuticals Inc — how do they compare? CoreWeave trades at $82.28 (market cap $44.99B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: CoreWeave is far larger — about 401× Inovio Pharmaceuticals Inc's market cap, and CoreWeave is more actively traded (41,993,776 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 7 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| CRWV | INO | |
|---|---|---|
Market Cap | $44.99B | $112.19M |
Volume | 41,993,776 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $143.08 | $2.65 |
52-Week Low | $60.82 | $0.66 |
Typical Hold Time | 7 Days | 43 Days |
Enterprise Value | $91.06B | $83.51M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →